Co-Diagnostics, Inc. CODX
Regular-session close
After hours · Nov 20, 7:41 PM ET
- YTD
- -97.45%
- 1 year
- -98.66%
5D -0.1015 (-43.94%)
- Market cap
- 1.36M
- Revenue (ttm)
- 7.32M
- EPS (ttm)
- -21.71
- Shares out
- 31.93M
- Forward P/E
- -0.62
- YTD return
- -97.45%
- 1-year return
- -98.66%
- 50-day average
- 1.06
- Volume
- 1.14M
- Avg volume
- 2.01M
- Open
- 0.14
- Previous close
- 0.1646
- Day's range
- 0.1276 – 0.1421
- 52-week range
- 0.1295 – 11.61
- Beta
- -0.85
- Price target
- 1.50 (+1058.3%)
Key statistics
- 200-day average
- 1.19
- Enterprise value
- -11.98M
- Price / sales
- 3.18
- Price / book
- 0.36
- Revenue growth
- -73.90%
- Free cash flow
- -12.79M
- Total cash
- 37.66M
- Total debt
- 2.37M
- Return on equity
- -50.57%
- Short % of float
- 0.76%
Fundamental scorecard
6 of 25 checks passed on CODX’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.33 | -0.32 | +0.01 | +3.03% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | -0.25 | +0.09 | +26.47% |
| Aug 8, 2024 | Jun 1, 2024 | -0.34 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.21 | -0.31 | -0.10 | -47.62% |
| May 9, 2024 | Mar 1, 2024 | -0.21 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | -0.50 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 12, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Jun 17, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| May 13, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Mar 15, 2024 | HC Wainwright & Co. | main | Neutral | Neutral |
| Dec 29, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- codiagnostics.com
News
Why Gap Shares Are Trading Higher By Around 4%; Here Are 20 Stocks Moving Premarket
Co-Diagnostics Announces Reverse Stock Split
12 Health Care Stocks Moving In Tuesday's Intraday Session
Co-Diagnostics Receives Logix Smart® ZDC Test Order from Peru Distributor as Dengue Cases Rise and Exhibits at MEDICA 2026 in Düsseldorf
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session Co-Diagnostics Q3 EPS $(1.01) Beats $(1.25) Estimate, Sales $282.881K Beat $169.000K Estimate
12 Health Care Stocks Moving In Tuesday's Pre-Market Session Co-Diagnostics Announces Publication Of Peer-Reviewed Study Using SARAGENE Human Papillomavirus High Risk Test Manufactured By CoSara Diagnostics
Co-Diagnostics Moves Closer to Commercial Tuberculosis Test Launch in India
Your note
Sign in to keep a note on CODX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABBOTT RICHARD DAVID | President | Stock Award(Grant) | Nov 21, 2024 | 13,915 |
| BROWN BRIAN LEE | Chief Financial Officer | Stock Award(Grant) | Nov 21, 2024 | 419,905 |
| DURENARD EUGENE A | Director | Conversion of Exercise of derivative security | Nov 21, 2024 | 163,333 |
| EGAN DWIGHT H. | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 21, 2024 | 522,858 |
| MURPHY TED | Director | Conversion of Exercise of derivative security | Nov 21, 2024 | 175,833 |
| NELSON JAMES B | Director | Conversion of Exercise of derivative security | Nov 21, 2024 | 163,333 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 5.58% | 1,781,283 | 1.30M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.78% | 567,722 | 413.93K | Sep 29, 2024 |
| Blackrock Inc. | 1.58% | 504,382 | 367.74K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.01% | 321,275 | 234.24K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.85% | 272,900 | 198.97K | Sep 29, 2024 |
| Susquehanna International Group, LLP | 0.59% | 187,569 | 136.76K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4.01% | 1,279,125 | 932.61K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.39% | 444,776 | 324.29K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.85% | 272,900 | 198.97K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 172,056 | 125.45K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.22% | 69,770 | 50.87K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.17% | 53,201 | 38.79K | Oct 30, 2024 |
